Cumulative Rates of Serious and Adverse Events of Special Interest in Vaccinees Following AZD1222 (ChAdOx1 nCoV-19): Results from a UK Post-authorisation Active Surveillance Study

被引：0
|
作者：
Evans, Alison [1 ]
Roy, Debabrata [1 ]
Davies, Miranda [1 ]
Dhanda, Sandeep [1 ]
Shakir, Saad [1 ]
机构：
[1] Drug Safety Res Unit, Southampton, Hants, England
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2024年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
1528
引用
收藏
页码：693 / 693
页数：1
相关论文
共 40 条
  • [31] Prevalence and determinants of adverse events following ChAdOx1 nCoV-19 vaccination (COVISHIELD) - A retrospective cohort study among healthcare workers in central Karnataka, India
    Davalagi, Shubha B.
    Nayak, Vaman P.
    Ghose, Anisha
    Marakatti, Siddarth S.
    Kasturi, Eshwar S.
    Maganahalli, Anurupa S.
    JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2023, 12 (11) : 2869 - 2874
  • [32] Safety of AZD1222 COVID-19 vaccine and low Incidence of SARS-CoV-2 infection in Botswana following ChAdOx1(AZD1222) vaccination: A single-arm open-label interventional study - final study results
    Makhema, Joseph
    Shava, Emily
    Izu, Alane
    Gaolathe, Tendani
    Kuate, Lesego
    Walker, Adam
    Carty, Lucy
    Georgiou, Panayiotis
    Kgathi, Coulson
    Choga, Wonderful T.
    Sekoto, Tumalano
    Seonyatseng, Ngozana
    Mogashoa, Tuelo
    Maphorisa, Comfort N.
    Mohammed, Terence
    Ntalabgwe, Tshenolo
    Frank, Tshepho T.
    Matlhaku, Boitumelo
    Diphoko, Ame
    Phindela, Thandie
    Kaunda, Agripa
    Kgari, Poloko
    Kanyakula, Thomas
    Palalani, Gape
    Phakedi, Isabella
    Mmalane, Mompati
    Taylor, Sylvia
    Moyo, Sikhulile
    IJID REGIONS, 2024, 10 : 35 - 43
  • [33] Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK (vol 397, pg 99, 2021)
    Voysey, M.
    Clemens, S. A. C.
    Madhi, S. A.
    LANCET, 2021, 397 (10269): : 98 - 98
  • [34] Anti-SARS-CoV-2 Spike Protein RBD Antibody Levels After Receiving a Second Dose of ChAdOx1 nCov-19 (AZD1222) Vaccine in Healthcare Workers: Lack of Association With Age, Sex, Obesity, and Adverse Reactions
    Lee, Sang Won
    Moon, Ji-Yong
    Lee, Sun-Kyung
    Lee, Hyun
    Moon, SeolHwa
    Chung, Sung Jun
    Yeo, Yoomi
    Park, Tai Sun
    Park, Dong Won
    Kim, Tae-Hyung
    Sohn, Jang Won
    Yoon, Ho Joo
    Kim, Sang-Heon
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [35] Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls
    Pakvisal, Nussara
    Sainamthip, Panot
    Teeyapun, Nattaya
    Luangdilok, Sutima
    Wanlapakorn, Nassamon
    Yorsaeng, Ritthideach
    Poovorawan, Yong
    Pakvisal, Piyapoom
    Susiriwatananont, Thiti
    Zungsontiporn, Nicha
    Sriuranpong, Virote
    Tanasanvimon, Suebpong
    Wanchaijiraboon, Passakorn
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (06)
  • [36] Adverse events following the first dose of Covishield (ChAdOx1 nCoV-19) vaccination among health workers in selected districts of central and western Nepal: A cross-sectional study
    Subedi, Prativa
    Yadav, Gopal Kumar
    Paudel, Binod
    Regmi, Anu
    Pyakurel, Prajjwal
    PLOS ONE, 2021, 16 (12):
  • [37] Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study
    Clemens, Sue Ann Costa
    Jepson, Brett
    Bhorat, Qasim E.
    Ahmad, Abdullahi
    Akhund, Tauseefullah
    Aley, Parvinder K.
    Bansal, Himanshu
    Bibi, Sagida
    Kelly, Elizabeth J.
    Khan, Mark
    Lambe, Teresa
    Lombaard, Johan J.
    Matthews, Sam
    Milan, Eveline Pipolo
    Olsson, Urban
    Ramasamy, Maheshi N.
    Paiva, Maria Sanali Moura de Oliveira
    Seegobin, Seth
    Shoemaker, Kathryn
    Szylak, Ameena
    Villafana, Tonya
    Pollard, Andrew J.
    Green, Justin A.
    LANCET MICROBE, 2024, 5 (08):
  • [38] Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland
    Ramasamy, Maheshi N.
    Kelly, Elizabeth J.
    Seegobin, Seth
    Dargan, Paul, I
    Payne, Ruth
    Libri, Vincenzo
    Adam, Matthew
    Aley, Parvinder K.
    Martinez-Alier, Nuria
    Church, Alison
    Jepson, Brett
    Khan, Mark
    Matthews, Sam
    Townsend, G. Todd
    Vekemans, Johan
    Bibi, Sagida
    Swanson, Phillip A.
    Lambe, Teresa
    Pangalos, Menelas N.
    Villafana, Tonya
    Pollard, Andrew J.
    Green, Justin A.
    LANCET MICROBE, 2023, 4 (11): : e863 - e874
  • [39] Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005)
    Koen, Anthonet L.
    Izu, Alane
    Baillie, Vicky
    Kwatra, Gaurav
    Cutland, Clare L.
    Fairlie, Lee
    Padayachee, Sherman D.
    Dheda, Keertan
    Barnabas, Shaun L.
    Bhorat, Qasim Ebrahim
    Briner, Carmen
    Ahmed, Khatija
    Bhikha, Sutika
    Bhiman, Jinal N.
    du Plessis, Jeanine
    Esmail, Aliasgar
    Horne, Elizea
    Hwa, Shi-Hsia
    Oommen-Jose, Aylin
    Lambe, Teresa
    Laubscher, Matt
    Malahleha, Mookho
    Benade, Gabriella
    McKenzie, Shakeel
    Oelofse, Suzette
    Patel, Faeezah
    Pillay, Sureshnee
    Rhead, Sarah
    Rodel, Hylton
    Taoushanis, Carol
    Tegally, Houriiyah
    Thombrayil, Asha
    Villafana, Tonya L.
    Gilbert, Sarah
    Pollard, Andrew J.
    Madhi, Shabir A.
    VACCINE, 2023, 41 (23) : 3486 - 3492
  • [40] Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial
    Madhi, Shabir A.
    Kwatra, Gaurav
    Richardson, Simone, I
    Koen, Anthonet L.
    Baillie, Vicky
    Cutland, Clare L.
    Fairlie, Lee
    Padayachee, Sherman D.
    Dheda, Keertan
    Barnabas, Shaun L.
    Bhorat, Qasim Ebrahim
    Briner, Carmen
    Ahmed, Khatija
    Aley, Parvinder K.
    Bhikha, Sutika
    Bhorat, A. E.
    Esmail, Aliasgar
    Horne, Elizea
    Kaldine, Haajira
    Mukendi, Christian K.
    Madzorera, Vimbai Sharon
    Manamela, Nelia P.
    Masilela, Mduduzi
    Hermanus, S. Tandile
    Motlou, Thopisang
    Mzindle, Nonkululeko
    Oelofse, Suzette
    Patel, Faeezah
    Rhead, Sarah
    Rossouw, Lindie
    Taoushanis, Carol
    van Eck, Samuel
    Lambe, Teresa
    Gilbert, Sarah C.
    Pollard, Andrew J.
    Moore, Penny L.
    Izu, Alane
    LANCET INFECTIOUS DISEASES, 2023, 23 (03): : 295 - 306
1234